Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Schering-Plough Pharmaceutical To Transfer 45 Percent Stock

This article was originally published in PharmAsia News

Executive Summary

Shanghai Schering-Plough Pharmaceutical, a joint venture 55 percent owned by Schering-Plough (China) Ltd., recently listed 45 percent of its equity-30 percent owned by Shanghai Pharmaceutical Industry Co. and 15 percent by Shanghai Pharmaceutical (Group)-on Shanghai United Assets and Equity Exchange for 66.329 million yuan (9.5 million). The two Chinese partners' pullout paves the way for Schering-Plough (China) to gain full control of Shanghai Schering-Plough Pharmaceutical; according to transfer terms, the foreign MNC has first rights to bid for the shares. Shanghai Schering-Plough Pharmaceutical has to defer to the policies of majority shareholder Schering-Plough (China) for its supplies and product export; thus any third-party deal will need the latter's blessings. (Click here for more - Chinese Language)
Advertisement

Related Content

Schering Plough To Buy Out Shanghai Partners
Advertisement
UsernamePublicRestriction

Register

SC068566

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel